FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155360123> ?p ?o ?g. }

• W2155360123 endingPage "1293" @default.
• W2155360123 startingPage "1283" @default.
• W2155360123 abstract "Purpose: To report the results of two studies on the use of dorzolamide as adjunctive therapy to timolol in patients with elevated intraocular pressure (IOP). In the larger study, the additive effect of dorzolamide administered twice daily also was compared with 2% pilocarpine. Methods: Both studies were parallel, randomized, double-masked, placebo-controlled comparisons. In the pilot study, 32 patients received 0.5% timolol twice daily plus either 2% dorzolamide twice daily or placebo twice daily for 8 days. In the Pilocarpine Comparison Study, 261 patients received 0.5% timolol twice daily plus 0.7% dorzolamide twice daily, 2% dorzolamide twice daily, 2% pilocarpine four times daily, or placebo (twice daily or 4 times daily) for 2 weeks. Patients then entered a 6-month extension period and received 0.5% timolol twice daily plus either 0.7% dorzolamide twice daily, 2% dorzolamide twice daily, or 2% pilocarpine four times daily. Results: In the pilot study, after 8 days, additional mean percent reductions in IOP for 2% dorzolamide and placebo were 17% and 3% at morning trough and 19% and 2% at peak, respectively. In the Pilocarpine Comparison Study, after 6 months, additional mean percent reductions in IOP (morning trough) were 9%, 13%, and 10% for 0.7% dorzolamide, 2% dorzolamide, and 2% pilocarpine, respectively. Patients receiving 2% pilocarpine had the highest rate of discontinuation due to a clinical adverse experience, and the use of dorzolamide was not associated with systemic side effects commonly observed with the use of oral carbonic anhydrase inhibitors. Conclusion: Dorzolamide twice daily was effective and well tolerated by the patients in these studies as adjunctive therapy to timolol. The larger study demonstrated that both concentrations of dorzolamide produce similar IOP-lowering effects to 2% pilocarpine. Purpose: To report the results of two studies on the use of dorzolamide as adjunctive therapy to timolol in patients with elevated intraocular pressure (IOP). In the larger study, the additive effect of dorzolamide administered twice daily also was compared with 2% pilocarpine. Methods: Both studies were parallel, randomized, double-masked, placebo-controlled comparisons. In the pilot study, 32 patients received 0.5% timolol twice daily plus either 2% dorzolamide twice daily or placebo twice daily for 8 days. In the Pilocarpine Comparison Study, 261 patients received 0.5% timolol twice daily plus 0.7% dorzolamide twice daily, 2% dorzolamide twice daily, 2% pilocarpine four times daily, or placebo (twice daily or 4 times daily) for 2 weeks. Patients then entered a 6-month extension period and received 0.5% timolol twice daily plus either 0.7% dorzolamide twice daily, 2% dorzolamide twice daily, or 2% pilocarpine four times daily. Results: In the pilot study, after 8 days, additional mean percent reductions in IOP for 2% dorzolamide and placebo were 17% and 3% at morning trough and 19% and 2% at peak, respectively. In the Pilocarpine Comparison Study, after 6 months, additional mean percent reductions in IOP (morning trough) were 9%, 13%, and 10% for 0.7% dorzolamide, 2% dorzolamide, and 2% pilocarpine, respectively. Patients receiving 2% pilocarpine had the highest rate of discontinuation due to a clinical adverse experience, and the use of dorzolamide was not associated with systemic side effects commonly observed with the use of oral carbonic anhydrase inhibitors. Conclusion: Dorzolamide twice daily was effective and well tolerated by the patients in these studies as adjunctive therapy to timolol. The larger study demonstrated that both concentrations of dorzolamide produce similar IOP-lowering effects to 2% pilocarpine." @default.
• W2155360123 created "2016-06-24" @default.
• W2155360123 creator A5002368112 @default.
• W2155360123 creator A5004439732 @default.
• W2155360123 creator A5004780321 @default.
• W2155360123 creator A5012671046 @default.
• W2155360123 creator A5014828280 @default.
• W2155360123 creator A5015532094 @default.
• W2155360123 creator A5024757777 @default.
• W2155360123 creator A5025380614 @default.
• W2155360123 creator A5025640273 @default.
• W2155360123 creator A5027732604 @default.
• W2155360123 creator A5028174729 @default.
• W2155360123 creator A5030643163 @default.
• W2155360123 creator A5030747987 @default.
• W2155360123 creator A5033515776 @default.
• W2155360123 creator A5035224599 @default.
• W2155360123 creator A5037290515 @default.
• W2155360123 creator A5038348561 @default.
• W2155360123 creator A5038914849 @default.
• W2155360123 creator A5042154323 @default.
• W2155360123 creator A5045714238 @default.
• W2155360123 creator A5047479802 @default.
• W2155360123 creator A5055305568 @default.
• W2155360123 creator A5058312368 @default.
• W2155360123 creator A5062096539 @default.
• W2155360123 creator A5062127850 @default.
• W2155360123 creator A5068650498 @default.
• W2155360123 creator A5068759484 @default.
• W2155360123 creator A5069160165 @default.
• W2155360123 creator A5076606360 @default.
• W2155360123 creator A5076639457 @default.
• W2155360123 creator A5081702964 @default.
• W2155360123 creator A5082770399 @default.
• W2155360123 creator A5083190969 @default.
• W2155360123 date "1996-08-01" @default.
• W2155360123 modified "2023-10-18" @default.
• W2155360123 title "The Use of Dorzolamide and Pilocarpine as Adjunctive Therapy to Timolol in Patients with Elevated Intraocular Pressure" @default.
• W2155360123 cites W1449256536 @default.
• W2155360123 cites W2000111716 @default.
• W2155360123 cites W2004519308 @default.
• W2155360123 cites W2014664159 @default.
• W2155360123 cites W2023593813 @default.
• W2155360123 cites W2046550322 @default.
• W2155360123 cites W2051410408 @default.
• W2155360123 cites W2114975414 @default.
• W2155360123 cites W2124997139 @default.
• W2155360123 cites W2157890401 @default.
• W2155360123 cites W2170476126 @default.
• W2155360123 doi "https://doi.org/10.1016/s0161-6420(96)30509-5" @default.
• W2155360123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8764800" @default.
• W2155360123 hasPublicationYear "1996" @default.
• W2155360123 type Work @default.
• W2155360123 sameAs 2155360123 @default.
• W2155360123 citedByCount "58" @default.
• W2155360123 countsByYear W21553601232012 @default.
• W2155360123 countsByYear W21553601232015 @default.
• W2155360123 countsByYear W21553601232022 @default.
• W2155360123 crossrefType "journal-article" @default.
• W2155360123 hasAuthorship W2155360123A5002368112 @default.
• W2155360123 hasAuthorship W2155360123A5004439732 @default.
• W2155360123 hasAuthorship W2155360123A5004780321 @default.
• W2155360123 hasAuthorship W2155360123A5012671046 @default.
• W2155360123 hasAuthorship W2155360123A5014828280 @default.
• W2155360123 hasAuthorship W2155360123A5015532094 @default.
• W2155360123 hasAuthorship W2155360123A5024757777 @default.
• W2155360123 hasAuthorship W2155360123A5025380614 @default.
• W2155360123 hasAuthorship W2155360123A5025640273 @default.
• W2155360123 hasAuthorship W2155360123A5027732604 @default.
• W2155360123 hasAuthorship W2155360123A5028174729 @default.
• W2155360123 hasAuthorship W2155360123A5030643163 @default.
• W2155360123 hasAuthorship W2155360123A5030747987 @default.
• W2155360123 hasAuthorship W2155360123A5033515776 @default.
• W2155360123 hasAuthorship W2155360123A5035224599 @default.
• W2155360123 hasAuthorship W2155360123A5037290515 @default.
• W2155360123 hasAuthorship W2155360123A5038348561 @default.
• W2155360123 hasAuthorship W2155360123A5038914849 @default.
• W2155360123 hasAuthorship W2155360123A5042154323 @default.
• W2155360123 hasAuthorship W2155360123A5045714238 @default.
• W2155360123 hasAuthorship W2155360123A5047479802 @default.
• W2155360123 hasAuthorship W2155360123A5055305568 @default.
• W2155360123 hasAuthorship W2155360123A5058312368 @default.
• W2155360123 hasAuthorship W2155360123A5062096539 @default.
• W2155360123 hasAuthorship W2155360123A5062127850 @default.
• W2155360123 hasAuthorship W2155360123A5068650498 @default.
• W2155360123 hasAuthorship W2155360123A5068759484 @default.
• W2155360123 hasAuthorship W2155360123A5069160165 @default.
• W2155360123 hasAuthorship W2155360123A5076606360 @default.
• W2155360123 hasAuthorship W2155360123A5076639457 @default.
• W2155360123 hasAuthorship W2155360123A5081702964 @default.
• W2155360123 hasAuthorship W2155360123A5082770399 @default.
• W2155360123 hasAuthorship W2155360123A5083190969 @default.
• W2155360123 hasConcept C118487528 @default.
• W2155360123 hasConcept C118552586 @default.
• W2155360123 hasConcept C142724271 @default.
• W2155360123 hasConcept C204787440 @default.
• W2155360123 hasConcept C27081682 @default.
• W2155360123 hasConcept C2776727336 @default.

• next